Cerebrospinal fluid liquid biopsy by low-pass whole genome sequencing for clinical disease monitoring in pediatric embryonal tumors

• DOI: 10.1093/noajnl/vdae126
• Publication Date: 2024-07-25T10:59:08Z
• Authors: Erin E Crotty; Vera A Paulson; Rebecca Ronsley; Nicholas A Vitanza; Amy Lee; Jason Hauptman; Hannah E Goldstein; Christina M Lockwood; Sarah E S Leary; Bonnie L Cole
• Keywords: Liquid biopsy

Liquid biopsy assays that detect cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) are a promising tool for disease monitoring pediatric patients with primary central nervous system (CNS) tumors. As compliment to tissue-derived molecular analyses, CSF liquid has the potential transform risk stratification, prognostication, and precision medicine approaches.